Hi-Tech’s ECR subsidiary to market two acquired products
AMITYVILLE, N.Y. — Hi-Tech Pharmacal has acquired marketing and distribution rights for a product designed to treat coughs and upper respiratory symptoms associated with an allergy or a cold.
The generic drug maker said it attained rights for TussiCaps, available in 10-mg/8-mg and 5-mg/4-mg formulations, from Mallinckrodt. Hi-Tech’s ECR Pharmaceuticals subsidiary, which markets branded prescription products, will promote TussiCaps, the only extended-release prescription cough-cold capsule product approved by the Food and Drug Administration.
In related news, Hi-Tech also recently acquired the marketing and distribution rights to an abbreviated new drug application filing from KVK-Tech for an antihistamine/decongestant product — dexbrompheniramine maleate 6-mg/pseudoephedrine sulfate 120-mg extended release tablets — which will be marketed by ECR under the brand name Lodrane.
Walgreens elevating presence in Empire State
NEW YORK — Walgreens has renewed its lease on the ground floor of the Empire State Building, and exchanged 10,000 sq. ft. of retail space on the concourse level to 10,000 sq. ft. on the second floor near the observatory exit elevators, according to a report published by REBusiness Online Thursday.
"The all-glass second-floor store is slated for a first quarter 2012 completion," the report stated. Walgreens’ lease in the Empire State Building is for a 15-year term and totals 18,818 sq. ft.
Alterna ventures into nail fungal solutions under Kerasal foot care brand
WHIPPANY, N.J. — Alterna earlier this week launched Kerasal Nail – Fungal Nail Renewal Treatment, a topical formula clinically proven to improve appearance of nails damaged or discolored by fungus and psoriasis.
In a consumer research study of 500 fungal nail suffers, 77% said they would definitely or probably buy Kerasal Nail after seeing the concept. Alterna has dedicated $5 million in advertising and promotion to launch Kerasal Nail to the U.S. market, with heavy focus on television, print and consumer promotion. The company expects to add at least $10 million of incremental retail sales to the category annually.
An estimated 30 million Americans suffer from unsightly nail appearance, a market currently underserved by nonprescription products. Kerasal Nail’s unique nail-penetrating formula has been licensed exclusively for the U.S. market from Moberg Derma, a Swedish pharmaceutical company. The product already is the No. 1 seller in various European countries where it launched last year, Alterna reported.
In the most recent clinical study, more than 90% of users saw improvement in nail appearance after eight weeks, and more than 75% saw improvement in appearance in just two weeks of use.
Kerasal Nail’s patented formula combines the keratolyctic, nail softening and hydrating effects of propylene glycol, urea and lactic acid to deeply penetrate the nail and restore healthy appearance by normalizing thickened nails, reducing nail discoloration and hydrating brittle nails. Kerasal Nail is odorless and preservative free.
The product will be found on store shelves in the foot care aisles in major Walmart stores and Rite Aid stores this fall.